Macular Society funded research

Since 1987 the Macular Society has invested over £5.1 million in 73 different research projects. Each year we invite applications for research grants and PhD studentships which are assessed by our Research Committee.

Line of professionals

The following research projects are currently being funded by the Macular Society. 

Dr Amanda-Jayne Carr, University College London Institute of Ophthalmology

£170,000
Using induced pluripotent stem cells to investigate Best associated macular degeneration. Dr Carr aims to create models of Best disease using induced pluripotent stem cells (iPSCs) to define the role of the gene BEST1 in the progression of Best disease and potentially identify new treatment pathways. 

Dr Aparna Lakkaraju, University of Wisconsin-Madison

£126,000
Modulating mitochondrial dynamics in the retinal pigment epithelium as a therapeutic strategy for macular dystrophies. The aims of this study are to first investigate mitochondrial functions in the healthy retinal pigment epithelium and examine how these are affected by vitamin A metabolites and oxidative stress. Secondly, the researchers will investigate how efficiently the retinal pigment epithelium removes damaged mitochondria, under normal and stressed conditions.

Professor Paul Foster, University College London Institute of Ophthalmology

£53,510
Realising the potential of the UK Biobank Research Resource. The aim of the project is to establish the frequency and characteristics of early AMD (separated by drusen type) in the UK Biobank cohort and relate this to genetic, lifestyle and biochemical data.

Dr John-Paul Taylor, Newcastle University

£92,998
Treating visual hallucinations in people with macular degeneration: a non-invasive stimulation study. This project is aiming to determine whether non-invasive transcranial direct current stimulation (tDCS) can be used to treat Charles Bonnet Syndrome in people with macular degeneration.

Professor Robin Walker, Royal Holloway University of London

£44,676
Investigating reading with a loss of central vision. Presenting text dynamically on an electronic display has an advantage over conventional page format in allowing large text to be presented. The aim of this project is to provide an evaluation of reading performance among people with AMD when using text presented on a moving electronic display, as opposed to a static screen or printed page. A second theme will examine the effectiveness of using an iPad or tablet with scrolling text as a device for training people in the eccentric reading technique. This will inform and improve the training offered by the Macular Society.

Dr Pádriag Mulholland, Ulster University

£99,333
Exploring the spatiotemporal summation of microperimetric stimuli in AMD. The aim of this project is to explore how the visual system collects light energy over space and time and how this can be incorporated into light sensitivity tests to monitor the onset and progression of AMD. By establishing the best spots of light for use in microperimetric tests for AMD, vision changes may be detected earlier, progression of AMD may be more effectively monitored and quality of life in AMD predicted more accurately.

Professor Paul Bishop, University of Manchester

£169,318
Development and utilisation of Manchester Eye Tissue Repository (METR) to elucidate the molecular pathology of AMD. This proposal aims to continue to develop the METR and to use some of the collected tissue and tissue extracts to answer key research questions. The aim is to compare genetic material and proteins from eye tissue with high genetic risk with similar tissue from eyes with low genetic risk.

Professor Majlinda Lako, Newcastle University

£169,845
Understanding the role of autophagy in the pathogenesis of AMD using a patient-specific iPSC model. The project aims to evaluate two important interlinked factors in the origin and development of AMD, namely complement activation and impairment of autophagy, a natural intracellular process that deals with the destruction and removal of old cell components. The project will use a robust model of AMD created in a laboratory from induced pluripotent stem cells, which displays key features typical of AMD. Identifying if cellular recycling is an underlying cause of AMD could lead to new drug treatments to treat the disease directly in its early stages preventing its progression and later consequences.

Professor Graeme Black, University of Manchester

£164,042

A comprehensive molecular analysis and iPSC model of early adult-onset macular degeneration (EOMD) to better understand AMD. EOMD affects people in the same way as AMD but at a younger age. The aim of the study is to understand the genetic and molecular mechanisms underpinning EOMD, including the role of the protein FHL-1. They will also investigate how retinal stem cells made from patients with EOMD behave and whether we can use them as a model of AMD. 

Dr Amanda-Jayne Carr, University College London Institute of Ophthalmology

£170,000

Investigating CRISPR/Cas9 gene editing as a therapy for Autosomal Dominant Bestrophinopathies. The aim of this project is to test whether CRISPR/Cas9 gene editing can be used as a treatment for autosomal dominant bestrophinopathies. In an autosomal dominant condition a faulty gene from one parent overrides the healthy gene from the other parent. The faulty gene creates a toxic protein which damages the cells of the retinal pigment epithelium (RPE) leading to sight loss. In this project they aim to cure dominant bestrophinopathies by using gene editing to cut out the faulty gene and leave the healthy one untouched. They will test whether it is working as planned using patients' skin cells, as well as stem cells and RPE cells created from patient skin cells.

Professor Majlinda Lako, Newcastle University

£169,584

Exploiting the role of exosomes to treat AMD and provide biomarkers for early diagnosis of disease. The project will investigate whether exosomes, small bubble-like structures released by RPE cells, play a role in development of AMD and whether any drugs known to affect exosome production elsewhere in the body can be used to change the production of RPE exosomes. This study also aims to identify if specific forms of exosomes can act as markers of AMD and potentially to identify people at particular risk of losing vision.

Dr Rob Collin, Radboud University, The Netherlands

£119,170 Co-funded with Retina UK

Natural exon skipping in ABCA4 mRNA and its modulation as a novel generic therapy for Stargardt disease. Stargardt disease is usually caused by mutations in the ABCA4 gene, which contains the instructions for making a specific protein. In some people with later-onset Stargardt disease, bits of genetic code are mistakenly 'skipped', the resulting protein is not normal and does not function as it should. This project aims to understand how and why bits of the gene are 'skipped' and prevent the misreading of the gene that causes damaging protein to be produced. The project will also look at the whole ABCA4 gene to work out what is causing pieces to be skipped and use manmade molecules to try to prevent it happening.

Dr Tamsin Callaghan, City, University of London

£77,731

Investigating the impact of patient-practitioner communication in age-related macular degeneration. Advice relating to lifestyle changes for AMD currently given to patients may reduce progression of disease. The study aims to provide a new framework for eye care professionals that is designed to improve the advice they give to patients, to ensure adherence to advice and which could lead to improved prognosis.

Dr Bridgeen Callan, Ulster University

£91,398

A polymersomal based eye-drop formulation to enhance delivery of drug payloads to the posterior of the eye. This project aims to develop an eye-drop based treatment that can deliver drugs to the back of the eye, to replace the need for intravitreal injections. It will be using small nanoparticles that aim to transport and deliver drugs to the macula where they are needed. The study hopes that these eye-drops could replace the use of repeated eye injections for wet AMD patients.

Dr Pearse Keane, University College London and Moorfields Eye Hospital NHS Foundation Trust

£126,461

Evaluation of age-related macular degeneration using artificial intelligence and optical coherence tomography. This project will be using AI to analyse retinal scans and detect patterns in the progress of AMD, from early AMD to late stage wet or dry AMD. By understanding how and why some people progress the aim is to be able to treat wet AMD earlier before vision loss occurs, and to better understand the scarring and atrophy which leads to vision loss in dry AMD.

Professor Paul McGraw, University of Nottingham

£167,081

Promoting functional vision through modern digital technology. Investigating how new digital technology can help those with central vision loss due to AMD. Using software that utilises the peripheral vision which is still clear in AMD patients, they aim to test ways to present text and images to improve clarity, reading speed and facial recognition.

Dr Giuliana Silvestri, Royal Hospitals, Belfast

£154,706

Efficacy and safety of the Scharioth Macular Lens in advanced macular disease. Clinical trial investigating the use of a magnifying lens inside the eye which can improve near sight. The study aims to understand whether the lens is safe and effective in improving vision for those with AMD or inherited retinal disease which cause central vision loss.

Dr James Whiteford, Queen Mary University of London

£148,991

A novel peptide-based therapy for wet age related macular degeneration. Study looking at syndecan-3, a protein that can inhibit new blood vessel formation. Researchers have isolated the portion of the protein which is involved in this process and are testing to see whether this can be used as a treatment to stop the growth of blood vessels in wet AMD. This small portion of the protein (peptide) will be compared against other wet AMD treatments.

 

Donate to research